SNAP-8 (acetyl octapeptide-3): what the research shows
- By Reed Calder
- Last reviewed Nov 12, 2026
- 21 studies and official documents checked
In short
SNAP-8 is a lab-made peptide of eight amino acids: the six of Argireline plus two more. It is sold in serums, as a powder to mix at home, and as vials marketed for injection, all as a Botox alternative. We found four studies of products that contain it, two microneedle patches and two serums, and each held other active ingredients, so no result can be credited to SNAP-8 alone. Large wrinkle figures such as “up to 63%” are maximums from the maker’s own tests; one published description of the maker’s split-face cream test gives up to 38% and an average of 7.1%. We found no study of SNAP-8 injected into any animal or person, none of how deep it gets into skin, and none comparing it with Argireline or Botox. It isn’t a drug.
EvidenceCellAnimalHumanfour studies, all of mixed products; none of SNAP-8 alone
You’ll often read that SNAP-8 is about 30% stronger than Argireline, cuts wrinkles by 63%, and can be mixed at home or injected. This page covers what it is, what each study in people actually tested, where the big numbers come from, how it compares with Argireline, and where it stands legally.
Names and forms you’ll see
| Name | What it is | Studied in people? |
|---|---|---|
| SNAP-8 | A trade name for the peptide below, sold by its maker as “SNAP-8 peptide solution” (Lubrizol; FDA GSRS) | Only inside mixed products |
| Acetyl octapeptide-3 | The ingredient name on labels (FDA GSRS) | Same as SNAP-8 |
| Acetyl octapeptide-1, acetyl glutamyl heptapeptide-3 | Other names the FDA registry lists for the same substance (FDA GSRS) | Same as SNAP-8 |
| Argireline (acetyl hexapeptide-8) | A different, six-amino-acid peptide that SNAP-8 extends. Some pages give SNAP-8 the name acetyl hexapeptide-8 by mistake (FDA GSRS). See the Argireline page | Yes, alone and in mixes |
| SNAP-8 vials, “booster” concentrates | Powder or liquid sold to mix into a serum, or marketed for injection | No study of either |
CAS numbers
A CAS number is a substance’s chemical registry number. Some “research” vials list it in place of a name. A different number usually means a different form, such as a salt, or a different substance. The registry lists the amide form.
| Form | CAS number | Registry record |
|---|---|---|
| SNAP-8 (acetyl octapeptide-3), amide form | 868844-74-0 | FDA GSRS |
What SNAP-8 is
SNAP-8 is the peptide Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2: Argireline’s six amino acids with alanine and aspartic acid added (FDA GSRS; FDA GSRS). It weighs about 1,073 (PubChem).
It is described as a copy of part of SNAP-25, a nerve protein, that competes with it, so less of the chemical signal reaches the muscle. That description comes from the maker’s material, as reported in a review (Errante et al., 2020). We found no test of that action in a living person.
A 2026 review treats it as a related commercial peptide, not a clinically interchangeable substitute for Argireline (Yi et al., 2026).
What has been studied
In people: only in mixed products
- 24 people, 2024. A dissolving patch held SNAP-8, a vitamin C form and a skin-moisture ingredient. It went on one eye and a plain hyaluronic acid patch on the other, nightly for 14 days and then every third day to day 28. 21 people finished. On day 28 all five roughness measures differed from the plain patch (p below 0.05), and skin water loss fell on days 7 and 14. No adverse effects. The study was supported by the patch maker (Shin et al., 2024).
- 12 weeks, patches with five actives, 2020. Hyaluronic acid microneedle patches with SNAP-8, two other peptides, adenosine and seaweed extracts were put on the outer eye corner of healthy people with aged skin. Fine lines were 25.8% lower and hydration 15.4% higher. The abstract names no control group, and the product was well tolerated (Avcil et al., 2020).
- 50 women, 24 weeks, a serum with many actives, 2023. One of the ingredients was SNAP-8. 47 of the 50 finished, there was no control group, and the investigator scored improvement. The research was paid for by the company behind the product, and the two authors work for it or consult for it (Draelos and Diaz, 2023).
- 12-week serum study, 2023. A facial serum containing SNAP-8 improved skin measures against the women’s own baseline, and a skin-sample test used an untreated control. The authors are employees of a company that funded it (Moy et al., 2023).
- Alone, on skin or by injection. We found no published study of SNAP-8 by itself in people, and no registered trial (ClinicalTrials.gov search).
EvidenceCellAnimalHumanmixed products only
Where the big numbers come from
- The maker’s own page. “Up to 72% reduction in maximum depth of wrinkle.” It names no study, group size or control (Lubrizol).
- An earlier version of the claim. A 2020 review, quoting the maker’s website, gave a best wrinkle reduction of 62% and a mean of 35%, and a lab test with 43% less glutamate release at 1.5 millimolar (Errante et al., 2020).
- A described maker test. A 2023 paper by a skin-care company’s staff describes a 28-day split-face study of a cream with 3% of a 0.05% SNAP-8 solution: wrinkle depth was lowered “by up to 38%,” and by 7.1% on average (Moy et al., 2023).
These three numbers come from the same maker’s material and don’t agree. “Up to” is the best result in the best spot; the average is the number most people would see.
The usual claims, checked
| Claim | Verdict | What the studies found |
|---|---|---|
| It works like Botox | Untested | No study in people measured muscle movement after SNAP-8. The mechanism comes from the maker’s description (Errante et al., 2020). For its shorter relative, Argireline, a 2025 review found no skin-application study that confirmed muscle inhibition (see Argireline) |
| It cuts wrinkles by up to 63% | Mixed | The large figures are maximums from the maker’s own tests: up to 62% with a mean of 35% in a 2020 review, up to 72% on the maker’s page now, and up to 38% with an average of 7.1% in a described split-face cream study (Errante et al., 2020; Moy et al., 2023; Lubrizol). No independent test of SNAP-8 alone |
| It is about 30% more active than Argireline | Untested | We found no head-to-head study in people. The maker’s lab numbers in a 2020 review compare SNAP-8 with a different peptide, Leuphasyl, not with Argireline (Errante et al., 2020) |
| Results show in a week | Untested | In a 24-person trial a patch with three actives lowered one roughness measure by day 7, and the gap from the plain patch was significant from day 14 (Shin et al., 2024). That can’t be credited to SNAP-8. We found no study of SNAP-8 alone at any time point |
| It gets through the skin | Untested | We found no skin-penetration study of SNAP-8. It weighs 1,073, above the 500-dalton rule of thumb (Bos and Meinardi, 2000), and Argireline, which is smaller, mostly stayed on the surface in a lab test (Kraeling et al., 2015). Two of the four tests in people used microneedle patches (Shin et al., 2024; Avcil et al., 2020) |
| Injecting it works | Untested | We found no study of SNAP-8 injected into any animal or person. Injection schedules and doses online don’t come from SNAP-8 research |
| It is safe, with no side effects | Mixed | No adverse effects in the patch studies of 24 people over 28 days and of a 12-week study (Shin et al., 2024; Avcil et al., 2020). We found no safety panel review of SNAP-8; the panel’s 0.005% limit is for Argireline’s ingredient (Johnson et al., 2025) |
| Microneedle patches or stamping make it work | Mixed | A patch with SNAP-8 and two other ingredients beat a plain patch for roughness on day 28 (Shin et al., 2024), and a 12-week patch study with five actives reported fewer fine lines without a control group (Avcil et al., 2020). Neither tested SNAP-8 alone, and we found no study of home stamping |
| It works better mixed with GHK-Cu or hyaluronic acid | Untested | No study tested SNAP-8 with a named partner. The serum studies used many ingredients at once, so no partner can be credited (Draelos and Diaz, 2023; Moy et al., 2023). For GHK-Cu, see the GHK-Cu page |
| A 3% to 10% serum is the right strength | Untested | The maker lists a 3% to 10% use level for its solution and doesn’t give the solution’s peptide content on that page (Lubrizol). In the one maker study described in print, the cream held 3% of a 0.05% solution (Moy et al., 2023). No study compared strengths |
| It is FDA-approved as an ingredient | Contradicted | Cosmetic ingredients need no FDA approval, so none is approved (FDA, 2025) |
| SNAP-8 is the same as Argireline | Contradicted | No. SNAP-8 has eight amino acids and Argireline six, and the FDA registry lists them as separate substances (FDA GSRS; FDA GSRS) |
Verdict key. Supported: controlled data in people, or the official record, back it. Mixed: studies disagree, or the support is small or limited to one use. Untested: we found no study in people. Contradicted: the studies or record we found show no effect or the opposite.
SNAP-8 and Argireline
| SNAP-8 | Argireline | |
|---|---|---|
| Amino acids | Eight: Argireline’s six plus alanine and aspartic acid | Six |
| Mass | About 1,073 (PubChem) | About 887 (PubChem) |
| Studied alone in people | No study found | Small trials; see the Argireline page |
| Blinded camera test | None found | One: no difference between sides (Henseler, 2023) |
| Skin-penetration test | None found | About 0.22% of a 10% cream stayed in the outer layer of human skin (Kraeling et al., 2015) |
| Safety panel review | None found | Safe up to 0.005%; data insufficient above (Johnson et al., 2025) |
| Is one stronger? | Pages say about 30% more active; we found no head-to-head study | The older, better-studied peptide |
| Status | Cosmetic ingredient; not an approved drug | Cosmetic ingredient; not an approved drug |
What the strengths mean
Labels, maker pages and studies use different numbers, and the label usually doesn’t say what the number is a percentage of.
| Where | Strength | What it was |
|---|---|---|
| Lubrizol | Recommended use level 3 to 10% | The maker’s solution; the page gives no peptide content for it |
| Moy et al., 2023 | 3% of a 0.05% solution, about 0.0015% peptide by our arithmetic | A described 28-day split-face cream study: up to 38%, average 7.1% |
| Shin et al., 2024 | Not stated in the abstract | Patch with three actives, 24 people |
| Avcil et al., 2020 | Not stated in the abstract | Patch with five actives, 12 weeks |
| Draelos and Diaz, 2023 | Not stated in the abstract | Serum with many actives, 24 weeks |
Unlike Argireline, we found no safety limit set for SNAP-8, so no strength is known to be inside or outside one. These are strengths from studies, not advice for anyone to use.
Side effects and safety
- In the patch studies. No adverse effects were reported in 24 people over 28 days or in a 12-week study, and skin water loss fell, which the authors read as no sign of needle damage (Shin et al., 2024; Avcil et al., 2020).
- No panel review. We found no safety review of acetyl octapeptide-3 by the cosmetic ingredient panel. Its 0.005% limit is for Argireline’s ingredient (Johnson et al., 2025).
- Injected. No study of SNAP-8 injected into any animal or person. For its relative Argireline, a woman developed a serious infection after facial injections (see the Argireline page).
- What is in the bottle. We found no independent analysis of SNAP-8 serums, concentrates or vials.
- Not studied. SNAP-8 alone, pregnancy, children, long-term daily use, and any strength.
Side effects people report from online products aren’t covered here; they come from users, not studies.
Legal and approval status
- Not an approved drug. It is sold as a cosmetic ingredient, and cosmetics don’t need FDA approval (FDA, 2025).
- Not on the FDA’s lists. It doesn’t appear on the FDA’s safety-risk page or in its May 2026 compounding categories (FDA, 2026; FDA list, May 2026). That is not an approval.
- No registered trial. ClinicalTrials.gov lists no study of it (ClinicalTrials.gov search).
- Not in the October 2026 HHS policy. That temporary policy covers six other peptides (Reuters, 2026).
- Not named on the World Anti-Doping Agency’s 2026 list (WADA, 2026).
- “Research use only” vials and any injectable use aren’t approved.
What to look for if you research it
We don’t name or link sellers. These checks come from the studies and registries:
- The ingredient name. Look for acetyl octapeptide-3. If a page calls SNAP-8 “acetyl hexapeptide-8,” it has the wrong peptide (FDA GSRS; FDA GSRS).
- A percentage of what. Ask whether a figure such as 10% is the peptide or a diluted solution of it (see the strengths above).
- Whose study. Check whether a wrinkle figure is an average or a best case, and whether the patch, serum or cream also held other actives. A study with a plain-patch or placebo side is worth more than a before-and-after.
- Who paid. Three of the four studies above were funded or supported by the company behind the product, and we found no funding statement for the fourth (Shin et al., 2024; Draelos and Diaz, 2023; Moy et al., 2023).
- Not for injection. There is no study of it in people by that route.
Our guide to what to look for explains what each test on a lab report proves and which routes are legal; how to read a peptide study explains how to judge the studies sellers cite. For other skin peptides, see peptides for skin.
What’s still unknown
- Whether SNAP-8 alone does anything to wrinkles in people.
- Whether it reaches a nerve ending from a serum, or only a patch delivers enough.
- Whether it beats Argireline.
- What any strength is a percentage of, and what the safe range is.
- Whether injecting it does anything, or is safe.
Retracted and flagged studies
A retracted study has been pulled by its journal, usually for serious errors or misconduct, and its results shouldn’t be relied on. A withdrawn paper was pulled, often before final publication. An expression of concern means the journal has flagged a problem it is still looking into.
We check every study this page cites against PubMed and the Retraction Watch database, and search both for flagged studies that mention SNAP-8. We recheck every month. Last checked Nov 12, 2026.
We found no retracted, withdrawn or flagged studies that mention SNAP-8.
Studies this page relies on
| Study | Published in | Status |
|---|---|---|
| Bos and Meinardi, 2000 | Exp Dermatol | No retraction or concern |
| Kraeling et al., 2015 | Cutan Ocul Toxicol | No retraction or concern |
| Avcil et al., 2020 | J Cosmet Dermatol | No retraction or concern |
| Errante et al., 2020 | Front Chem | No retraction or concern |
| Moy et al., 2023 | J Cosmet Dermatol | No retraction or concern |
| Draelos and Diaz, 2023 | Dermatol Ther (Heidelb) | No retraction or concern |
| Henseler, 2023 | GMS Interdiscip Plast Reconstr Surg DGPW | No retraction or concern |
| Shin et al., 2024 | Ann Dermatol | No retraction or concern |
| Johnson et al., 2025 | Int J Toxicol | No retraction or concern |
| Yi et al., 2026 | Life (Basel) | No retraction or concern |
Bring your questions to other researchers
Our forum opens once 100 researchers join the waitlist. Members post studies, ask what they actually found, and answer with sources.
Questions
What is SNAP-8?
A lab-made peptide of eight amino acids, built from Argireline with two added. Its ingredient name is acetyl octapeptide-3 (FDA GSRS).
What does SNAP-8 do?
It is sold to soften expression lines. The four studies in people used patches or serums with other actives, and none shows what SNAP-8 does alone (Shin et al., 2024; Avcil et al., 2020).
Does SNAP-8 really work?
It is unproven. We found no study of SNAP-8 alone, and the big wrinkle figures are maximums from the maker’s own tests (Errante et al., 2020; Moy et al., 2023).
How quickly does SNAP-8 work?
No study of SNAP-8 alone measured this. A patch with three actives lowered one roughness measure by day 7 in 24 people, with a significant gap from the plain patch from day 14 (Shin et al., 2024).
What is the difference between SNAP-8 and Argireline?
SNAP-8 has eight amino acids and Argireline six. Argireline has small trials alone; SNAP-8 has none. See Argireline (FDA GSRS; FDA GSRS).
Is SNAP-8 the same as Botox?
No. It is a cosmetic peptide, and we found no study showing it relaxes a muscle in a person (Errante et al., 2020).
What should you mix with SNAP-8?
No study tested SNAP-8 with a named partner, so no mix has been shown to help or harm. The serum studies used many ingredients at once (Draelos and Diaz, 2023; Moy et al., 2023).
Can you inject SNAP-8?
We found no study of injected SNAP-8 in any animal or person. Injection doses online don’t come from SNAP-8 research, and we don’t give dosing advice.
Is SNAP-8 safe?
No adverse effects were reported in two small patch studies (Shin et al., 2024; Avcil et al., 2020). We found no safety panel review of it, and nothing on injection.
What do SNAP-8 before-and-after photos show?
Not much by themselves. The studies that mattered compared a patch with a plain patch on the other eye, and the product held other actives (Shin et al., 2024).
What strength of SNAP-8 do studies use?
The maker lists a 3% to 10% use level for its solution, and a described maker cream study used 3% of a 0.05% solution (Lubrizol; Moy et al., 2023). The patch studies don’t state an amount in the abstracts.
Does SNAP-8 get through the skin?
We found no test of it. Argireline, which is smaller, mostly stayed on the surface in a lab test (Kraeling et al., 2015).
Do microneedle patches or derma stamping help SNAP-8 work?
A patch with SNAP-8 and two other ingredients beat a plain patch in a 24-person trial. We found no study of home stamping (Shin et al., 2024).
Is SNAP-8 FDA approved or legal?
It isn’t an approved drug. It is sold as a cosmetic ingredient, which needs no FDA approval (FDA, 2025). Our guide to what to look for covers the routes people use.
Sources
- Shin JY, et al. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Ann Dermatol. 2024;36(4):215-224. PubMed 39082657
- Avcil M, et al. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J Cosmet Dermatol. 2020;19(2):328-337. PubMed 31134751
- Draelos ZD, et al. The Benefits of a Multimechanistic Antiaging Skin Technology. Dermatol Ther (Heidelb). 2023;13(12):3111-3119. PubMed 37861918
- Moy M, et al. Peptide-pro complex serum: Investigating effects on aged skin. J Cosmet Dermatol. 2023;22(1):267-274. PubMed 35426243
- Errante F, et al. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923. PubMed 33195061
- Yi KH, et al. Peptides in Aesthetic Dermatology: Classification, Fibroblast-Centered Mechanisms, Delivery Technologies, and Clinical Evidence. Life (Basel). 2026;16(10):1660. PubMed 42942246
- Kraeling ME, et al. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015;34(1):46-52. PubMed 24754410
- Henseler H. Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia® Complexion Analysis camera system for objective skin analysis. GMS Interdiscip Plast Reconstr Surg DGPW. 2023;12:Doc09. PubMed 38024099
- Johnson W, et al. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. Int J Toxicol. 2025;44(2_suppl):54S-63S. PubMed 40673537
- Bos JD, et al. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165-9. PubMed 10839713
- ClinicalTrials.gov. Search for SNAP-8, acetyl octapeptide-3 and acetyl octapeptide, November 12, 2026: no studies. Search
- Lubrizol. SNAP-8 peptide solution C (product page, read November 12, 2026). Product page
- U.S. Food and Drug Administration. FDA authority over cosmetics: how cosmetics are not FDA-approved, but are FDA-regulated. Content current as of November 18, 2025. FDA page
- U.S. Food and Drug Administration. Safety risks associated with certain bulk drug substances nominated for use in compounding. Content current as of April 22, 2026. FDA page
- U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A. Updated May 14, 2026. FDA document
- World Anti-Doping Agency. 2026 Prohibited List. WADA document
- Reuters. U.S. health department to allow temporary sale of some unapproved peptides. October 28, 2026. Article
- U.S. Food and Drug Administration. Global Substance Registration System: Acetyl Octapeptide-3 (UNII 8K14HJF88S). GSRS
- U.S. Food and Drug Administration. Global Substance Registration System: Acetyl Hexapeptide-8 Amide (UNII L4EL31FWIL). GSRS
Last reviewed Nov 12, 2026. Approval and compounding status change often; we recheck this page when they do. Nothing here is medical advice; see our medical disclaimer. Found a mistake? Email editors@peptideresearchstudy.com.